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Mycosis fungoides is a lymphoma that appears to begin 
in skin. Although variable in its clinical course, it tends 
to affect middle-aged people, is present for a median of 
4 yr before diagnosis, and generally results in death of 
the patient 4 to 5 yr after diagnosis. Cutaneous tumors 
and palpably enlarged lymph nodes are associated. with 
shortened survival, and each of these frequently IS ac-
companied by extracutaneous dissemination ~f th~ dis-
ease. The malignant cells are T lymphocytes With highly 
infolded nuclei, and they frequently express a helper cell 
function. Their chromosome complement has been found 
to be abnormal in karyotyping studies, and measure-
ment of the amount of DNA by cytophotometry may 
permit diagnosis of the disease ~efore ~he histological 
characteristics are detectable by light miCroscopy. 
Mycosis fungoides (MF) is a di~ease ~hose c~~p_lete mani-
festations have allowed ready diagnosis by clmJcians, have 
engendered confusion and disagreement among _histologists, 
and have provided, during the 1970s, a growth mdustry for 
immunologists. The disease was described 175 yr ago by Jean 
Louis Alibert, who was born in 1768 in Villefranche, ~ small 
town in the south of France. After being trained as a pnest, he 
returned home to teach, but the French Revolution w~s hard 
on priests and the new laws forced the then 24-yr-old Ahbert to 
change his profession. Because he could no longer ser~e God, 
he followed the next most honorable calling and became mstead 
the founder of French dermatology. He described many cuta-
neous afflictions, including lupus vulgaris, keloids, cutis laxa, 
and, in 1806, what is now called mycosis fungo~des. The 1st 
patient was a_ 56-yr-ol~ man with a scaly ,~rupti~,~ t hat pro-
gressed to pamless, skm-colored nodules. Late1, he noted, 
"the skin which covers the nodules opens, and each tubercle 
becomes a fetid ulcer. As decomposition progresses, these tu-
bercles take on a greenish-black color or a very dark violaceous 
tint. One can picture them as fruits rotting on the stem that 
bears them. By comparis~m even with the 1·avages of untr~ate~ 
tertiary syphilis these leswns are almost always more hornble. 
"After some months," he went on, "the patients fall little by 
little into a state of emaciation that weakens them to the 
extreme [and] they end up by succumbing or leading a miser-
able life for many yea1·s" [1]. 
This description covers the central features of the di~~ase as 
it is still seen. It starts as a nonspecific, scaly dermatitis, and 
infiltrated lesions develop gradually. These become frank nod-
ules and grow to form tumors that ulcerate and dest~·oy nori?al 
structures. Eventually, the patient becomes cachectic a~d dies, 
although there is great variability in the extent to ~luch t he 
disease progresses and in the time taken to reach the fmal stage. 
This review focuses on some of the data published in the past 
decade regarding (a) the clinical course of the disease an~ !ts 
response to treatment, (b) morphological cellular abnorma.htJes 
in the skin, lymph nodes, blood, and other tissues of MF 
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patients, and (c) studies on the functioning of the abnormal 
cells. The relevance of this discussion to the theme of this 
volume lies in a consideration of the likelihood that the behavior 
of the abnormal cells in these patients reflects at least in some 
aspects that of their normal counterparts and that this reflec-
tion may help us to understand normal cells better. 
CLINICAL FINDINGS 
Mycosis fungoides has been considered a capricious disease 
with an extremely variable clinical course. Undoubtedly, this 
partially valid characterization has been due to a lack of reports 
of large series of MF patients. Within the past decade, data on 
5 large groups of patients have been collected and reported in 
the U.S., and we now can be much more confident in speaking 
about the prognosis of these patients [2-6]. Most commonly, 
the disease develops in middle-aged people; a few are so unlucky 
as to have it before 20 yr of age, and a few do not get lesions 
until over 70 yr of age. In perhaps 85% of patients, the disease 
begins as a poorly defined, patchy, erythematous, and scaly 
eruption. In some patients these nonspecific changes persist for 
decades, but the median period between appearance of lesions 
and diagnosis by biopsy is approximately 4 YI" [2,3]. The nature 
of the lesions during the period of nonspecific changes is vari-
able and poorly defined. Often the eruption is diagnosed as 
eczema or psoriasis, but generally in retrospect the clinical 
appearance in such cases was not completely typical of these 
diseases. It is doubtful that completely typical psoriasis be-
comes MF, although by chance the two might afflict the same 
patient occasionally. There are intriguing anecdotal reports of 
patients whose disease began unquestionably as contact der-
matitis and then showed chronic changes and eventually be-
came frank MF. Cohen and associates [3] and subsequently 
Greene and co-workers [7] pointed out that patients with MF 
are more likely to be employed in manufacturing, in construc-
tion, or especially in the petrochemical industry where they 
may have been exposed to more than the usual contact irritants, 
allergens, and toxic materials. There is also a more specific pre-
MF condition-parapsoriasis en plaques. This condition is char-
acterized by variably sized areas of dull pink macules, some-
times with minimal scaling. These tend to spread over periods 
of months to years. They sometimes change location, i.e., dis-
appear in one area and develop in another. Sometimes they 
become poikilodermatous with atrophy, dyschromia, and telan-
giectasia. In small series of patients with this condition, 14 to 
46% were found later to have MF [8,9]. Methods for accurately 
predicting which patient will have a benign course and which 
a more malignant one would be usefu l because the usual light 
microscopic examination of affected tissue cannot differentiate 
the fatal from the nonfatal form of the disease. Yet another 
variant of what may be pre-MF was described a decade ago 
under the name of lymphomatoid papulosis [10]. Patients with 
this condition have red papules that may become pustular, 
ulcerate, heal in about 1 mo, and leave scars. The notable 
featme is spontaneous healing despite what may appear to be 
a highly malignant infiltrate. Although the condi tion was orig-
inally described as benign, some patients have been reported 
later to have frank MF [11], and we have seen several patients 
in San Francisco who have had coexisting typical lesions of MF 
and lymphomatoid papulosis. 
Once the clinician and the pathologist have agreed on the 
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diagnosis ofMF, the median survival is 3 to 5 yr [2,3]. Probably 
the most significant factors enabling prediction of survival after 
diagnosis are the types of lesions present on the skin and the 
presence or absence of palpably enlarged superficial lymph 
nodes. Tumors (as opposed to flatter lesions) or palpably en-
larged lymph nodes are associated with markedly shortened 
survival if present at the time of diagnosis; they also may 
develop later. A median survival rate of approximately 2 yr 
after the development of cutaneous tumors has been found in 
several series over several decades and appears not to have 
been changed appreciably by modern therapy. If one evaluates 
only lymph nodes accessible to palpation, one obviously cannot 
determine the size of many nodes. The value of bipedal lym-
phangiography in classifying the stage of MF is in dispute 
[12,13], but it is apparent that peripheral nodes are involved 
earlier and to a greater degree than more proximal nodes. This 
pattern of invasion has been elucidated further by fmdings at 
staging laparotomies in a small number of patients [14,15] and 
at autopsy in a large number of patients [16]. These studies 
have helped physicians explain the poor survival rate noted in 
patients with cutaneous tumors or palpably enlarged lymph 
nodes. Patients with tumors on their skin generally have extra-
cutaneous disease, and patients with lymph node MF found at 
autopsy all had MF in other tissues besides skin and lymph 
nodes. Hence it appears that the "banier" to dissemination is 
in skin, not lymph nodes. Once malignant cells have invaded 
the lymph nodes, they have also invaded other tissues. The 
lungs, spleen, and liver are the other organs most often invaded. 
Invasion of bone marrow occurs only infrequently, but essen-
tially all tissues may be invaded [2]. 
HISTOLOGY 
With light microscopy the diagnosis of MF relies on the 
overall pattern of cellular infiltration as well as on the cytologic 
abnormalities · of individual cells. The pattern is that of an 
infiltration of the upper dermis and, of especial note, of the 
epidermis. The cells infiltrating the epidermis may do so singly, 
but more characteristically they form small clusters, termed 
Pautrier microabscesses, in the lower epidermis. These mi-
croabscesses, although not pathognomonic of MF, are quite 
characteristic of the disease, and pathologists emphasize their 
presence in making the diagnosis. The cells in the epidermis 
are mononuclear and fairly homogeneous, whereas the infiltrate 
in the upper dermis is more heterogeneous and consists not 
only of mononuclear cells but also of inflammatory cells, in-
cluding polymorphonuclear leukocytes, eosinophils, and plasma 
cells. The mononuclear cells may vary in size and regularity, 
but some of them have a distinctive appearance, with a large 
hyperchromatic nucleus; it has been assumed that it is the 
latter type of cells that are malignant. When tumors develop, 
the pleomorphic character of the infiltrate diminishes, and the 
inflammatory infiltrate with a few malignant cells seen in the 
initial skin biopsy sample is replaced by the more· abundant 
population of malignant-appearing mononuclear cells seen at 
autopsy [16]. It is cells with this appearance that invade extra-
cutaneous sites. They infiltrate diffusely rather than in large 
nodules so that a generally normal parenchymal architecture is 
preserved. Although in the past systemic spread of MF was 
interpreted clinically and histologically as conversion to a more 
classic form of lymphoma such as Hodgkin's disease [17], the 
current interpretation is that MF remains a unique disease 
whether in the skin or at extracutaneous sites [16). 
ELECTRON MICROSCOPY 
When investigation of the disease was limited to macroscopic 
and light microscopic observations, the nosologic uniqueness of 
MF remained in question. The observation that began what 
might be considered the current era of investigation into MF 
was the electron microscopic discovery by Lutzner and Jordan 
[18] of a previously undescribed type of cell in the blood of 
patients with what is now accepted by most to be the leukemic 
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FIG 1. Electron microscopic appearance of cell from the skin of a 
patient with mycosis fungoides. The nucleru· contour index of this cell 
is 13 (photograph cow·tesy of Scott McNutt, M.D.). 
phase or variant of MF, the Sezary syndrome. This cell has a 
large, deeply infolded nucleus with peripheral condensation of 
the electron-opaque chromatin. Subsequently, Lutzner, Hobb , 
and Horvath [19] found similar cells in the skin lesions of 
patients with Sezary syndrome and with MF. The specificity of 
this cell has been questioned because the original investigators, 
as well as others [20], found morphologically similar cells in 
patients with conditions unrelated to MF (e.g., lichen planus). 
Furthermore, 5 to 10% of peripheral blood leukocytes incubated 
for 72 hr with phytohemagglutinin show cerebriform nuclei 
resembling those in patients with Sezary syndrome [21). None-
theless, most pathologists still believe that these cerebriforn1 
cells are characteristic of MF, and they appear to be present in 
large numbers only in this disease. Sometimes they are seen in 
lymph nodes that by light microscopy show only the benign 
changes of dermatopathic lymphadenopathy; their presence 
suggests that routine light microscopic examination "underdi- ' 
agnoses" lymph node invasion and this may explain the known 
bad prognosis of palpably enlarged lymph nodes even when the 
diagnosis is benign by routine examination. The confusion 
regarding the significance of these leukocytes in the diagnosi 
of MF has been reduced considerably by a study recently 
completed by McNutt and Crain. • They quantified the degree 
of nuclear irregularity in cells from the skin of 16 patients with 1 MF and in cells from more than 100 patients with other disease 
By measuring the length of the nuclear membrane and by 
dividing this value by the square root of the cross-sectional 
area, they computed a nuclear contour index (NCI) and com-
pared this value in the 2 groups of patients. The mean NCI was 
6.1 in patients with MF and 4.6 to 5.4 in patients with other 
diseases. By setting the limit at an NCI of:::: 6.1 and by requiring1 that :::: 6% of the lymphocytes have NCI :::: 9, they obtained a 
false-positive rate of only 1%. No cell with an NCI as high as 16 
• McNutt NS, Crain WR, unpublished data. 
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was found in any benign infiltrate (FigUl'e 1), but such cells 
were seen in some of the skin samples from patients with MF. 
This work confirmed the impressions of past workers that cells 
with extremely irregular nuclear shapes were pathognomonic 
of MF and that the whole population of lymphocytes in the 
skin of MF patients had nuclei with abnormally irregular con-
tours. 
ABNORMAL CELL FUNCTIONING 
Research next turned to elucidation of membrane and nuclear 
characteristics of the cells in MF. The seminal observation was 
published in 1971 when Crossen and co-workers [22] studied 
abnormal-appearing leukocytes from the blood of a patient with 
Sezary syndrome. They noted that the Sezru·y cells responded 
to phytohemagglutinin and concluded that the cells were of the 
lymphocytic series. Their conclusion was not original, but it did 
represent the 1st time that nonmorphological evidence had 
been presented to support the conclusion. Within the next 3 yr, 
groups in New York [23], Paris [24], and Bethesda [25] dem-
onstrated that the abnormal cells had the membrane charac-
teristics of thymus-derived cells and could form sheep eryth-
rocyte rosettes. Electron microscopic study of the cells at the 
center of such rosettes confirmed that the cerebriform cells 
described by Lutzner and co-workers were indeed T cells. 
Circulating cells in patients with Sezar.v syndrome or cells 
teased from skin tumors [26] shared these characteristics. More 
recently, antibodies to human T cell antigen were used to show 
the distribution of the cells within tissue sections [27], and the 
cells in Pautrier abscesses as well as the dermis carried this 
antigen. Furthermore, in an in vitro system, circulating cells 
from 5 of 12 patients with Sezary syndrome stimulated normal 
B cells to produce immunoglobulin and thus served as helper T 
cells [28]; cells of the other 7 patients were presumably less well 
differentiated and did not retain this capacity. 
CHROMOSOME ABNORMALITIES 
Crossen and associates [22] examined the kru·otypes of the 
Sezary cells t hat phytohemagglutinin stimulated to divide and 
found definite aneuploidy. Their observation has been con-
firmed by several investigators; it is clear that chromosomal 
abnormali t ies occw· in skin, lymph nodes, peripheral blood 
leukocytes, and even occasionally in bone marrow. These are 
more common when there are histologically abnormal cells at 
these sites, but they can be found even when such abnormalities 
are not detectable by light microscopy [29]. No single chromo-
somal abnormality seems to be characteristic of MF or the 
Sezary syndrome. Van Vloten, Van Duijn, and Schaberg [30] 
have used the finding of abnormal complement of chromosomes 
to improve diagnostic acumen beyond that attainable by light 
microscopy. They measured the DNA content of cells from 
patients with MF and Sezary syndrome as well as from patients 
only suspected of having MF but in whom routine light micro-
scopic examination was not definitive. They predicted accu-
rately which of the patients suspected of having MF would 
subsequently show histologically typical MF. In addition, they 
used this technique to separate patients with dennatopathic 
lymphadenopathy into 2 groups with markedly different prog-
noses. Van Vloten, Schaberg, and Van der Ploeg observed that 
cells from skin lesions of 5 patients with lymphomatoid papu-
losis had markedly abnormal DNA contents even though the 
lesions continued to involute spontaneously [31]. 
Thus, in one decade we have passed from a time when the 
existence of MF was seriously questioned to a time when there 
is widespread agreement about the general outlines of the 
clinical course and that the disease is a malignancy of helper T 
cells with an a bnormal chromosomal complement diagnosable 
by techniques other than traditional light microscopy. 
The sites of production of these cells, however, have not been 
proved. Clinicians see a disease that apperu·s to be strictly 
cutaneous for years, and topical chemotherapy or electron beam 
irradiation limited to the skin can produce prolonged remission 
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and perhaps even CUl'es [5]; these facts favor the view that the 
abnormal cells multiply in the skin itself. However, areas of 
skin involvement are not contiguous, and therefore the disease 
m~st be multifocal, or the cells must have some early ability to 
migrate, probably through the bloodstream, to new skin sites. 
There are reports of circulating tumor cells in patients with 
disease otherwise apparently limited to cutaneous plaques 
[32], an indication that dissemination occurs via the blood-
stream. It may be that in early stages of the disease the cells 
have such an affinity for skin that the overwhelming majority 
of them reside in it, where repeated doses of cytotoxic ch emicals 
or irradiation can kill them, and that th e repetition of such 
regimens eliminates the circulating cells when they return to 
the skin. Such a migration between skin and blood, of course, 
was suggested most elegantly by the successful management, 
through leukapheresis, of skin lesions in a patient with a high-
count Sezary syndrome [33]. However, preliminary studies in 
which 3H-thyrnidine was injected into patients with advanced 
disease suggested that although malignant cells in the skin can 
divide and those in the. blood cannot, the bulk of circulating 
Sezru·y cells are produced extracutaneously [34]. 
SUMMARY 
I have tried to present an overview of MF and to emphasize 
some of its clinical aspects, including the generally prolonged 
course with an infiltrate that is both clinically and histologically 
banal initially but that becomes obviously malignant even-
tually. Just as multifocal eosinophilic granuloma may be a 
proliferation of 1 type of nonkeratinocyte epidermal cell-the 
Langerhans cell-so MF may be a proliferation of a different 
type of nonkeratinocyte epidermal cell-a specialized T lym-
phocyte that is a normal component of skin-associated lymph-
oid t issue [35]. 
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